PharmaSuisse Models for Evidence-based Therapeutic Decision- making and Therapeutic Management Martine Ruggli Pharmacist FPH pharmaSuisse Switzerland.

Slides:



Advertisements
Similar presentations
Some issues raised by the implementation of integrated care for patients with chronic diseases National Implementation of Innovations in Integrated Care.
Advertisements

AU European Forum, Divonne mars 2004 Michel Buchmann Dr pharmacien In the last ten years, two new professionnal services have been developped in.
Role of the Pharmacist in Collaborative Care for Mental Health and Addiction Treatment in Medically Underserved Appalachia Sarah T. Melton, PharmD,BCPP,CGP.
Portugal Economic Evaluation Applied to Decision Making Isaura Vieira INFARMED, I.P. – National Authority for Medicines and Health Products I Pan-American.
ECONOMIC ASSESSMENT OF IMPLEMENTATION TREATMENT GUIDELINES OF HYPERTENSION IN OUT-PATIENT PRACTICE Kulmagambetov IR Karaganda State Medical Academy, Kazakhstan.
Drug Utilization Review (DUR)
TRAINING FOR ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN HOSPITALS JUNE 2014.
Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
1. 2 Implementing and Evaluating of an Evidence Based Nursing into Practice Prepared By Dr. Nahed Said El nagger Assistant Professor of Nursing H.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Clinical Pharmacy Basma Y. Kentab MSc..
1 Monitoring medical prescription in the Opole Voivodeship Branch of the NFZ Roman Kolek M.D.
Part 2  In community-based long-term care, the resident may simply need assistance with taking their medications at the right time or with preparing.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Physicians’ acceptance of pharmaceutical medication reviews in an institution for the Elderly Buchmann S 1, Krähenbühl J.M 2, Nyffeler R 3, Buchmann M.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Impact of a public education program on promoting rational use of medicines: a household survey in south district of Tehran, Darbooy SH, Hosseini.
 Definitions  Goals of automation in pharmacy  Advantages/disadvantages of automation  Application of automation to the medication use process  Clinical.
Module 3. Session DCST Clinical governance
Why are we learning this? How scientific knowledge (pharmacology, therapeutics) and clinical skills (measuring blood pressure, glucoses, drug information)
Pharmaceutical Economics Heng-Sim Lee RPh MS Director of Pharmacy, ChiaYi Branch, Taichung Veterans General Hospital Clinical Nutritional.
IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE
The Role Of The Dementia Care Home Liaison Nurse Within South East Essex Jackie Smith Clinical Nurse Specialist Dementia Care Home Liaison Nurse.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
Introducing the Medication Recording System Schedule Ed Castagna Mom & Pop’s Small Business Services.
Dispensing to in and out patients or Drug distribution system
Efficiency improvement of primary care prescription by physicians - pharmacists cooperating in quality circles Ruggli M. 1, Nyffeler R. 3, Duay B. 4, Repond.
Bryan Bray, Pharm.D., CPP Chief Operating Officer Medication Management, LLC Vice President of Clinical Services Piedmont Pharmaceutical Care Network,
24/04/ Optimization of the prescription in collaboration with the physician: the role of the clinical pharmacist CLINICAMP IV.
Infection Control Clinical Pharmacy and Patient Safety
The Value of Medication Therapy Management Services.
LDL Program Medical Management Philip E. Johnston, Pharm.D.
Clinical Pharmacy Part 2
Problems of Polypharmacy
Delmar Learning Copyright © 2003 Delmar Learning, a Thomson Learning company Nursing Leadership & Management Patricia Kelly-Heidenthal
1. Patient- centered care 2. Partnering (with patients, other providers, communities) 3. Quality improvement (measuring care delivery and outcomes; learning.
Antipsychotic Utilization: Oregon State Medicaid Ann M. Hamer, PharmD BCPP This presentation was made possible by a grant from the State Attorney General.
Expectations for the provision of medicines Dr Michel Buchmann FIP Vice President 48th GIRP Annual General Meeting 18th June 2007, GENEVA.
ACCESS TO MEDICINES - POLICY AND ISSUES
Medicines optimisation – a research pharmacist’s perspective Dr David Alldred Senior Lecturer in Pharmacy Practice 23 January 2015Bradford School of Pharmacy1.
Origin and Process of Utah Guidelines Anna Fondario, MPH Utah Department of Health Violence and Injury Prevention Program.
NPS MEDICINEWISE Lynn Weekes Chief Executive.
The present situation and future prospects for the pharmacist’s renumeration in Switzerland: A reorientation toward new paid professionnal services Are.
Using drug use evaluation (DUE) to optimise analgesic prescribing in emergency departments (EDs) Karen Kaye, Susie Welch. NSW Therapeutic Advisory Group*
Danielle Elore COHP 450 Ferris State University PICO PRESENTATION: FOR HOSPITALIZED PATIENTS, DOES THE USE OF HYPNOTIC AGENTS AS COMPARED WITH NON- PHARMACEUTICAL.
Warm-up List 5 influences on your choice of health care products or services. Circle the two that most often affect your decisions Remember yesterday we.
FINANCIAL IMPACT OF JUDICIOUS USE OF MEDICINE IN PRIMARY CARE Zuo, Yeqin; Morrell, Stephen; Dartnell, Jonathan; Wu Fred; Weekes, Lynn NPS: Better Choices,
An unpleasant sensory or emotional experience associated with actual or potential tissue damage The World Health Organization (WHO) has stated that pain.
Putting Patients at the Centre of Care What can my Community Pharmacist do for me? Dr Tarlochan Gill Chairman, Kent & Medway Pharmacy Local Professional.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Introduction 2. Pharmaceutical care is a professional patient care practice, which, when provided as an organized service, is experienced, documented,
The Holistic Approach to the Design and Meaningful Use of Electronic Health Records: A Nursing Experience Frances Beadle, MSc Health Informatics Nurse.
Documentation in Practice Dept. of Clinical Pharmacy.
School of Public Health Health Economics and Health Care Management University of Bielefeld Bielefeld (Germany), September 29th, 2015 Prof. Dr. Wolfgang.
Choosing Wisely Pharmacy’s Role and Recommendations Mary Wong
CONTROLLING THE COSTS OF HEMOPHILIA
Strategies to Reduce Antibiotic Resistance and to Improve Infection Control Robin Oliver, M.D., CPE.
Community Pharmacy: Sharing Our Vision
Prescribing.
Introduction to Clinical Pharmacy
Impact of a public education program on promoting rational use of medicines:
Communication Skills Lecture 1-2
Opioid-related harms and responses
Victoria Gemmell1 Professor Alex Mullen2
Pharmacy practice and the healthcare system Ola Ali Nassr
When and How to Treat UTI Section 4: The Role of the Pharmacist
Presentation transcript:

pharmaSuisse Models for Evidence-based Therapeutic Decision- making and Therapeutic Management Martine Ruggli Pharmacist FPH pharmaSuisse Switzerland

pharmaSuisse 1. Prescription data (benchmarking per physician and therapeutic class) 2. Education on guidelines, Evidence-based medecine and pharmacoeconomy. 3. Analysis of prescription attitudes in comparison with scientific and economic data and search for alternatives in drug market 4. Consensus of each quality circle 5. Application of the consensus 6. Check on the impact of the consensus 7. Assessment of the results and improvements Work process Continous quality improvement of prescription Resume of the expose 2 models : 1.Collaboration with physicians to improve prescription practice 3 applications implemented in Switzerland : o Quality circles physicians-pharmacists o Pharmacist consulting in nursing homes o Expertise of prescription profile of the physician. 2.Integrated Networks Pilot project in e-health

pharmaSuisse 1. Prescription data (benchmarking per physician and therapeutic class) 2. Education on guidelines, Evidence-based medecine and pharmacoeconomy. 3. Analysis of prescription attitudes in comparison with scientific and economic data and search for alternatives in drug market 4. Consensus of each quality circle 5. Application of the consensus 6. Check on the impact of the consensus 7. Assessment of the results and improvements Work process Continous quality improvement of prescription Level of collaboration between pharmacists and other healthcare professionals Quality circles Nursing home consulting

pharmaSuisse 7.Assessment of the results and improvements 1. Prescription data 2. Guidelines and Evidence-based medecine 3. Analysis of prescription attitudes in comparison with scientific and economic data and search for alternatives in drug market 4. Consensus 5. Application of the consensus 6. Check on the impact of the consensus 1. Prescription data (benchmarking per physician and therapeutic class) 2. Education on guidelines, Evidence-based medecine and pharmacoeconomy. 3. Analysis of prescription attitudes in comparison with scientific and economic data and search for alternatives in drug market 4. Consensus of each quality circle 5. Application of the consensus 6. Check on the impact of the consensus 7. Assessment of the results and improvements Work process Continous quality improvement of prescription First model: collaboration with the physician to improve prescription practice

pharmaSuisse Physicians-Pharmacists Quality Circle

pharmaSuisse 1. Prescription data (benchmarking per physician and therapeutic class) 2. Education on guidelines, Evidence-based medecine and pharmacoeconomy. 3. Analysis of prescription attitudes in comparison with scientific and economic data and search for alternatives in drug market 4. Consensus of each quality circle 5. Application of the consensus 6. Check on the impact of the consensus 7. Assessment of the results and improvements Work process Continous quality improvement of prescription What is a Physicians-Pharmacists Quality Circle ? A stable group of 5-15 GPs and 1-2 pharmacists as moderators Meeting voluntarily Evaluation of the daily prescribing practice Working together to continuously improve their practice This means that every participant is active!

pharmaSuisse 7.Assessment of the results and improvements 1. Prescription data (benchmarking per physician and therapeutic class) 2. Guidelines and Evidence-based medecine 3. Analysis of prescription attitudes in comparison with scientific and economic data and search for alternatives in drug market 4. Consensus of each quality circle 5. Application of the consensus 6. Check on the impact of the consensus 1. Prescription data (benchmarking per physician and therapeutic class) 2. Education on guidelines, Evidence-based medecine and pharmacoeconomy. 3. Analysis of prescription attitudes in comparison with scientific and economic data and search for alternatives in drug market 4. Consensus of each quality circle 5. Application of the consensus 6. Check on the impact of the consensus 7. Assessment of the results and improvements Work process Continous quality improvement of prescription Application of the model in physicians - pharmacists quality circles:

 Cercles de qualité pharmaSuisse Saving in 2009  170’000 € per physician M. Ruggli, O.Bugnon / 2009 Source de données brutes : OFAC (2009) Economic impact on drug cost: 11 years experience in Fribourg +1.7% +3.7%

pharmaSuisse More balanced attitude towards marketing strategies: example of aliskiren Better awarness of the risk of drugs: example of rimonabant Better use of the suitable drug: example of fluoroquinolone "Circle effect": more than just cost saving

A real collaborative practice and not a dream! The objectives: –optimize the safety and effectiveness of the treatments for the patients. –more efficient spreading of the pharmacovigilance messages –saving capacity on medicine costs based on professional decisions and not on price reductions. –increased resistance of the Healthcare professionals against industrial marketing activities. –recognized interdisciplinary education in favor of person- centered care. BUT it is absolutely necessary to be persistant to get results Quality circles after 11 years…which is the constancy?

Quality circles implemented in nursing homes: pharmacist consulting

-42 nursing homes -2'214 patients -22 pharmacists -Growth of the drugs cost -Modification of the Fribourg cantonal health legislation Dissemination and implementation of the service Development of pharmaceutical care services and research in a Swiss canton, Pharm World Sci, 2008

7.Assessment of the results and improvements 1. Prescription data Statistics of drug consumption in the nursing home 2. Guidelines and Evidence-based medecine 3. Report of the pharmacist: analysis of prescription and search for alternatives 4. Discussion of the report with all health care professionals of the nursing home and agreement on a consensus 5. Application of the consensus 6. Check on the impact of the consensus 1. Prescription data (benchmarking per physician and therapeutic class) 2. Education on guidelines, Evidence-based medecine and pharmacoeconomy. 3. Analysis of prescription attitudes in comparison with scientific and economic data and search for alternatives in drug market 4. Consensus of each quality circle 5. Application of the consensus 6. Check on the impact of the consensus 7. Assessment of the results and improvements Work process Continous quality improvement of prescription Application of the model in nursing home

Evaluation of the economic impact of this service in nursing homes Medications: «Implemented since 2002, pharmaceutical care services have allowed to decrease the costs in a dramatic way »

Evidence-based practice recommendations in psychogeriatrics for Elderly Pharmacological management of 1) cognitive symptoms of dementia and delirium; 2) behavioral and psychological symptoms of dementia (depression, sleep disturbances, agitation) 1.Need identification 2. Interdisciplinary working group 3. Systematic literature Review 4. Treatment algorithms 5. Dissemination, education 6. Evaluation

Publications

expertise of the prescription profile of the physician

1. Prescription data (detailed analysis to define the prescription profile) 2. Guidelines and Evidence-based medecine 3. Analysis of prescription attitudes in comparison with scientific and economic data 4. Highlight of the possible savings 5. Modification of the prescription if necessary 6. Check on the impact 1. Prescription data (benchmarking per physician and therapeutic class) 2. Education on guidelines, Evidence-based medecine and pharmacoeconomy. 3. Analysis of prescription attitudes in comparison with scientific and economic data and search for alternatives in drug market 4. Consensus of each quality circle 5. Application of the consensus 6. Check on the impact of the consensus 7. Assessment of the results and improvements Work process Continous quality improvement of prescription Application of the model in the expertise of the prescription profile of the physician

pharmaSuisse Annual survey from the health insurance to determinate the cost of the drugs prescribed by physicians during one year. If too high (30% more than the mean value) the physician gets a warning and has to justify his costs Other use of the prescription data of the physician

pharmaSuisse Analysis of the drug costs How can the pharmacist help ? Therapeutic classes Cost in 2007Cost in 2008 Antihypertensive drugs Hypercholesterolemia treatment Proton pump inhibitors NSAID Antiasthmatic drugs Antidepressant drugs Antidiabetics Antibiotics Analgesics Neuroleptics Anticoagulants Calcium channel blocker Tranquilizers Beta blockers Hypnotics Diuretics Vasodilatators Antacids

pharmaSuisse Cost = price * volume * frequency of prescription Parameters needed to understand where is the problem: cost per patient price per unit number of units par patient frequency of prescription How can the pharmacist help ?

pharmaSuisse PhysicianCost/patientPrice/unitUnit/patient Prescription frequency (%) Dr Friend Dr Collegue Dr Long Dr Friend Cost evolution of analgesics Difference 31000€62575€31575€ Dr Michel Buchmann, Fine analysis of the prescription of analgesics 2008

pharmaSuisse Dr Michel Buchmann, Fine analysis of the prescription of analgesics hydromorphoneAcetaminophenFentanylOxycodon Tramadol + acetaminphen

pharmaSuisse Dr Michel Buchmann, Hydromorphone: just for 1 patient This patient can’t take any other painkiller, using high dose of hydromorphone to be able to control his pain Cost of 22’223 € in 2008 that the physician can’t be made responsible for Other saving possible through generics substitution of all fentanyl originals: 2857 € Fine analysis of the prescription of analgesics

pharmaSuisse Dr Michel Buchmann, Same analysis for all the therapeutic classes Switch to generics But especially therapeutics switches towards better evaluated and less expensive drugs Example: ezetimibe => potent statin = saving of 1428 € per year nevibolol => bisoprolol or metoprolol = saving of 285 € BUT ALWAYS KEEP IN MIND THAT QUALITY IS THE CENTRAL POINT Next step: fine analysis of the prescription of all therapeutic classes

pharmaSuisse Based on the data of the quality circle, we showed that Dr Friend could reduce the drug costs but only in a small way (3 %). This demonstrates that these 10 years working in quality circle carried their fruits: Dr Friend is a physician aware of the drug costs, prescribing the best evaluated drugs, with the best economical potential; the extra costs are due to specific situations, not influenced by the prescriber Dr Friend absolutely satisfies the criteria of the health insurance. Dr Michel Buchmann, Analysis summary Letter for the Health Insurance:

pharmaSuisse To implement projects: what is important? Get recognised Get paid These services are new services that have to be remunerated separately.. Impossible with a margin system …. => Change the remuneration system and pay for services = THAT‘s the KEY All the projects are realised in ambulatory sector Keep im mind that politicians want to slow the costs’ growth

pharmaSuisse Where do we go?

pharmaSuisse 27/10/15 29 Integrated care « specialized » pharmaceutical services « basic » pharmaceutical services Consulting in nursing homes Quality circles physicians - pharmacists New direction: integrated care Pharmacist Patient Pharmacist Physician Patient

pharmaSuisse Pilot project: collaboration with telemedicine

pharmaSuisse Pharmacist specially trained to work with algorithms for different diseases Pilot project: collaboration with telemedicine If the patient needs a consultation, he is given the choice of visiting his physician if he has one or getting the service of a physician from Medgate, the biggest center for telemedicine of Switzerland

pharmaSuisse This contact with Medgate is realised via videoconsultation which enables the physician to see the patient Pilot project: collaboration with telemedicine physicians Discussion between physician, patient and pharmacist about the case and the treatment. If necessary, the treatment will be prescribed by the physician and delivered by the pharmacist directly If the case requires a bigger intervention, the patient will be oriented to a physician or an hospital

pharmaSuisse Future of the profession of pharmacists: Think services Think remuneration system partially based on fee for services Organise education Add motivation and enthusiasm! Conclusion

pharmaSuisse Thanks to Michel Buchmann Dominique Jordan and pharmaSuisse Olivier Bugnon and Jean-François Locca, University of Geneva

pharmaSuisse Thanks for your attention